$NRIX
Nurix Therapeutics, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021036448 Filed on July 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $7.091M $4.182M
YoY Change 69.56% -55.69%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.511M $3.270M
YoY Change 129.69% 74.87%
% of Gross Profit
Research & Development $25.99M $14.14M
YoY Change 83.81% 31.43%
% of Gross Profit
Depreciation & Amortization $648.0K $500.0K
YoY Change 29.6% -16.67%
% of Gross Profit
Operating Expenses $33.51M $17.41M
YoY Change 92.42% 37.86%
Operating Profit -$26.41M -$13.23M
YoY Change 99.65%
Interest Expense $171.0K $220.0K
YoY Change -22.27% 69.23%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$26.24M -$13.01M
YoY Change 101.71% 325.16%
Income Tax $100.0K -$20.59M
% Of Pretax Income
Net Earnings -$26.38M $7.580M
YoY Change -448.05% -347.07%
Net Earnings / Revenue -372.05% 181.25%
Basic Earnings Per Share -$0.60 $0.00
Diluted Earnings Per Share -$0.60 $0.00
COMMON SHARES
Basic Shares Outstanding 43.80M 3.732M
Diluted Shares Outstanding 43.80M 4.910M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $386.0M $173.3M
YoY Change 122.75%
Cash & Equivalents $188.2M $159.3M
Short-Term Investments $197.8M $14.20M
Other Short-Term Assets $4.581M $3.900M
YoY Change 17.46%
Inventory
Prepaid Expenses
Receivables $2.537M
Other Receivables $3.142M
Total Short-Term Assets $396.3M $196.8M
YoY Change 101.36%
LONG-TERM ASSETS
Property, Plant & Equipment $8.345M $5.800M
YoY Change 43.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $110.4M $9.100M
YoY Change 1113.63%
Other Assets $2.915M $1.600M
YoY Change 82.19%
Total Long-Term Assets $121.7M $16.50M
YoY Change 637.58%
TOTAL ASSETS
Total Short-Term Assets $396.3M $196.8M
Total Long-Term Assets $121.7M $16.50M
Total Assets $518.0M $213.3M
YoY Change 142.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.405M $4.900M
YoY Change 10.31%
Accrued Expenses $7.678M $4.200M
YoY Change 82.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.84M $34.40M
YoY Change 36.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $72.96M $72.30M
YoY Change 0.91%
Total Long-Term Liabilities $72.96M $72.30M
YoY Change 0.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.84M $34.40M
Total Long-Term Liabilities $72.96M $72.30M
Total Liabilities $119.8M $106.7M
YoY Change 12.28%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $398.2M -$61.53M
YoY Change
Total Liabilities & Shareholders Equity $518.0M $213.3M
YoY Change 142.84%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$26.38M $7.580M
YoY Change -448.05% -347.07%
Depreciation, Depletion And Amortization $648.0K $500.0K
YoY Change 29.6% -16.67%
Cash From Operating Activities -$31.53M -$14.43M
YoY Change 118.52% 8.17%
INVESTING ACTIVITIES
Capital Expenditures -$2.094M -$1.620M
YoY Change 29.26% 3140.0%
Acquisitions
YoY Change
Other Investing Activities -$55.02M -$720.0K
YoY Change 7542.08% -107.2%
Cash From Investing Activities -$57.11M -$2.340M
YoY Change 2340.47% -123.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 150.5M 119.7M
YoY Change 25.73% 299100.0%
NET CHANGE
Cash From Operating Activities -31.53M -14.43M
Cash From Investing Activities -57.11M -2.340M
Cash From Financing Activities 150.5M 119.7M
Net Change In Cash 61.83M 102.9M
YoY Change -39.92% -3181.14%
FREE CASH FLOW
Cash From Operating Activities -$31.53M -$14.43M
Capital Expenditures -$2.094M -$1.620M
Free Cash Flow -$29.44M -$12.81M
YoY Change 129.8% -3.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5940000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
298434000
CY2020Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
3846000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
90890000
CY2020Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
7500000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7511000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2537000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
176000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
59000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12391000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6672000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
170000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
177000
CY2020Q4 us-gaap Assets
Assets
396343000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3412000
CY2020Q4 nrix Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
8328000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
60685000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
850000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26243000
CY2021Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
171000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-20576000
us-gaap Net Income Loss
NetIncomeLoss
-4811000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43804066
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
82000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-57000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7662000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50714000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-57714000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
37000
CY2020Q1 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
31000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-69802000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
118000
CY2020Q2 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
22000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
474000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
82000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-61526000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1043000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2700000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-38000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-24275000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
270133000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
150157000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
241000
CY2021Q2 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
104000
us-gaap Profit Loss
ProfitLoss
-50657000
us-gaap Profit Loss
ProfitLoss
-4811000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1288000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
986000
us-gaap Share Based Compensation
ShareBasedCompensation
6644000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
119681000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2934000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1977000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59497000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21760000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
150157000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9737130
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3944000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-19000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26401000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
394000
CY2021Q1 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
40000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25994000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
33505000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26414000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-566000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-50000
us-gaap Share Based Compensation
ShareBasedCompensation
650000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
151830000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
12399000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
51454000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-671000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1885000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23482000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
26543000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
183238000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
29640000
nrix Proceeds From Sales Of Investments
ProceedsFromSalesOfInvestments
6994000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
9857000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
119914000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
631000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
177000
nrix Payments For Repurchase Of Unvested Early Exercised Stock Options
PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
1000
nrix Payments For Repurchase Of Unvested Early Exercised Stock Options
PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
1000
nrix Proceeds From Issuance Under Employee Stock Purchase Plan
ProceedsFromIssuanceUnderEmployeeStockPurchasePlan
1043000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
360000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-7500000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2537000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-704000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
19590000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
837000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2056000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2119000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1745000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
119730000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
68851000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
124513000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
119526000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34986000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
188377000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
159499000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
607000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
927000
nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
144000
nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
53000
nrix Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
916000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188207000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159329000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
170000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
170000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and investments. The Company&#8217;s investments consist of debt securities issued by highly rated corporate entities, the U.S. federal government or state and local governments. The Company&#8217;s exposure to any individual corporate entity is limited by policy. Deposits may, at times, exceed federally insured limits, but minimal credit risk exists. The Company invests its cash equivalents in highly rated money market funds. The Company has not experienced any credit losses on its deposits of cash and cash equivalents. </p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could differ materially from those estimates. </p>
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q2 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2021Q2 nrix Cash Cash Equivalents And Investments
CashCashEquivalentsAndInvestments
496500000
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.333
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-3
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22816000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19855000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14471000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13183000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4986000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5725000
CY2021Q2 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
1388000
CY2020Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
1238000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
703000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
591000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
74000
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
601000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
700000
CY2021Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2015Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P60M
CY2017Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-04-30
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
In November 2017, the Company entered into a second amendment to its original lease agreement that combined the Company’s two leases into a single lease agreement and extended the term of the lease agreement through April 30, 2025.
CY2021Q2 us-gaap Security Deposit
SecurityDeposit
91000
CY2020Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P14M
CY2020Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-07-31
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1592000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3897000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3986000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4105000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1732000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
15312000
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8153546
CY2021Q2 nrix Share Based Compensation Arrangement By Share Based Payment Award Options Shares Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesSubjectToRepurchase
95124
CY2021Q2 nrix Share Based Compensation Arrangements By Share Based Payment Award Options Exercise Value Of Shares Subject To Repurchase
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseValueOfSharesSubjectToRepurchase
400000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
48900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
CY2021Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
CY2020Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
nrix Percentage Of Net Operating Loss Carryover And Carryback Offset Of Taxable Income Cares Act
PercentageOfNetOperatingLossCarryoverAndCarrybackOffsetOfTaxableIncomeCARESAct
1.00
nrix Net Operating Loss Carryback Period Cares Act
NetOperatingLossCarrybackPeriodCARESAct
P5Y
CY2020 nrix Net Operating Loss Carryback Refund Claim Cares Act
NetOperatingLossCarrybackRefundClaimCARESAct
19600000
CY2020 nrix Income Taxes Refund Received On First Refund Claim Cares Act
IncomeTaxesRefundReceivedOnFirstRefundClaimCARESAct
16300000
CY2020 nrix Income Interest Received Cares Act
IncomeInterestReceivedCARESAct
600000
CY2021Q1 nrix Income Taxes Refund Received On First Refund Claim Cares Act
IncomeTaxesRefundReceivedOnFirstRefundClaimCARESAct
800000
CY2021Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
3100000
CY2021Q2 us-gaap Income Tax Examination Interest Accrued
IncomeTaxExaminationInterestAccrued
100000
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
7580000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26382000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50657000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4811000
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1177991
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5276651
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23502267
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5276651
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25280731

Files In Submission

Name View Source Status
0001564590-21-036448-index-headers.html Edgar Link pending
0001564590-21-036448-index.html Edgar Link pending
0001564590-21-036448.txt Edgar Link pending
0001564590-21-036448-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nrix-10q_20210531.htm Edgar Link pending
nrix-20210531.xml Edgar Link completed
nrix-20210531.xsd Edgar Link pending
nrix-20210531_cal.xml Edgar Link unprocessable
nrix-20210531_def.xml Edgar Link unprocessable
nrix-20210531_lab.xml Edgar Link unprocessable
nrix-20210531_pre.xml Edgar Link unprocessable
nrix-ex311_6.htm Edgar Link pending
nrix-ex312_8.htm Edgar Link pending
nrix-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending